110621 ⎘
ssRNA viruses negative-sense; Details; Arenaviridae New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS
#2RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING LASSA VIRUS GP OR NP, AND USES THEREOF
#3LIVE ATTENUATED JUNIN VIRUS AND RELATED COMPOSITIONS AND METHODS
#4MULTIVALENT MOPEVAC-BASED IMMUNOGENIC COMPOSITION FOR VACCINATION AGAINST NEW WORLD ARENAVIRUSES AND THERAPEUTIC USE(S) THEREOF
#5METHOD FOR PRODUCING AN ANTITUMORAL ARENAVIRUS AS WELL AS ARENAVIRUS MUTANTS
#6MODIFIED ARENAVIRUS PARTICLES EXPRESSING MUTANT KRAS, MUTATED CANCER DRIVER GENE, OR TUMOR-ASSOCIATED ANTIGEN AS CANCER IMMUNOTHERAPIES
#7ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS, METHODS AND USE THEREOF
#8ARENAVIRUSES AS VECTORS
#9PREFUSION-STABILIZED LASSA VIRUS GLYCOPROTEIN COMPLEX AND ITS USE
#10Lassa virus vaccine
#11Chimeric molecules and uses thereof
#12POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
#13VACCINES AND METHODS
#14Method for producing an antitumoral arenavirus as well as arenavirus mutants
#15VSV CHIMERIC VECTORS
#16NOVEL LASSA VIRUS RNA MOLECULES AND COMPOSITIONS FOR VACCINATION
#17NUCLEOTIDE VACCINE
#18Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity
#19Lassa vaccine
#20Chimeric molecules and uses thereof
#21Lassa virus vaccine
#22Compositions and methods for treating arenavirus infection
#23TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS
#24Modified arenavirus
#25Vaccines against hepatitis B virus
#26POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
#27LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors
#28Compositions and methods for measles virus inhibition
#29SOLUBLE AND MEMBRANE-ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS
#30Cross-protective arenavirus vaccines and their method of use
#31Compositions and methods for coronavirus inhibition
#32Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
#33Treatment of influenza virus infection
#34Multi-epitopic vaccine
#35LASSA VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
#36Method of inducing a CTL response
#37LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors
#38MELAN-A-CARRIER CONJUGATES
#39NUCLEOTIDE VACCINE
#40SOLUBLE AND MEMBRANE ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS
#41Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes
#42Packaging of Immunostimulatory Substances Into Virus-Like Particles: Method of Preparation and Use
#43Influenza virus inhibiting peptides
#44MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE
#45Method of inducing a CTL response
#46Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
#47Chimeric lyssavirus nucleic acids and polypeptides
#48Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins
#49Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
#50Influenza virus inhibiting peptides
#51Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
#52Hiv-peptide-carrier-conjugates
#53Melan-A- carrier conjugates
#54Method of inducing a CTL response
#55Methods for producing and using pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
#56Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
#57Chimeric lyssavirus nucleic acids and polypeptides